Skip to main

Safety inspection

Calling TB-500 safe requires human evidence

I want the paperwork before the reassurance. The interesting results are real; the compound named on the paperwork often changes.

A magnifier over a microscope slide beside an open cream notebook and cobalt pencil

The TB-500 peptide

“Safe” is a big word for a small fragment. TB-500 is a synthetic peptide, a short chain of amino acids, carrying the LKKTETQ stretch from thymosin beta-4. The full protein has 43 amino acids; the fragment corresponds to residues 17–23. The analytical work identifies TB-500 as the acetylated LKKTETQ fragment, while the structural work examines the parent protein’s grip on actin. Most of the repair literature concerns that larger protein.

That quiet substitution earns my distrust. A genuine finding can become a misleading claim simply by changing the substance’s name. Before asking how well TB-500 worked, I want to establish which molecule actually entered the experiment.

A 43-position protein strip with positions 17–23 highlighted beside the seven-position TB-500 fragment
The highlighted stretch identifies the fragment’s origin. Shared sequence alone establishes no clinical equivalence. Sources: Irobi and colleagues; Ho and colleagues.

Repair findings worth examining

The rat wound paper deserves its reputation for an interesting result. Full thymosin beta-4 increased re-epithelialization—the resurfacing of a wound—by 42% at four days and up to 61% at seven days versus saline. The same experiment recorded more collagen and new vessels. The combination helps explain the enthusiasm, and I share some of it.

Then comes the strength test. Dystrophin-deficient mice developed more regenerating muscle fibers without significant improvement in strength or cardiac function. Fibrosis, or scarring, remained elevated. For a recovery pitch, this experiment demands an answer. The muscle recovery page follows it through, alongside the ligament and exercise findings.

Is TB-500 safe?

The fragment has no completed controlled human trial in this record. The encouraging human tolerability result used full thymosin beta-4: 40 healthy volunteers received it intravenously in a Phase 1 study. That study found infrequent mild or moderate adverse events and no dose-limiting toxicities or serious adverse events. Its particular substance, route and observation period matter.

The biological concern is equally specific. Thymosin beta-4 promotes cell movement and vessel growth, processes implicated in tumor metastasis and angiogenesis in preclinical work. Human cancer risk from TB-500 remains unmeasured. My answer to that gap is to withhold reassurance. The side effects and safety page separates those concerns from anecdotal accounts.

The human exposure question

A trial registration can look impressive at a glance. The injectable thymosin beta-4 heart-attack study on ClinicalTrials.gov was withdrawn before enrollment. Nobody entered it. That small administrative fact changes how much human evidence the listing supplies.

The research inspection brings the fragment’s identity, actin sequestration, angiogenesis and human exposure data together. For the FDA record, the legal status page retains the distinction between a withdrawn nomination, a prescription decision and approval. Each question warrants an answer in its own terms; confidence in one cannot settle the others.